PRIVATE AND CONFIDENTIALPrivate and Confidential • January 20th, 2017 • Generex Biotechnology Corp • Pharmaceutical preparations • California
This letter confirms our understanding of the mutual present intentions of Generex Biotechnology Corporation (the "Purchaser") and Emmaus Life Sciences Inc. (the "Company") and, hereinafter also together referred to as the “Parties”, with respect to the principal terms and conditions under which the Purchaser will acquire a controlling interest of the outstanding capital stock of the Company for a total consideration of $225,000,000 (hereinafter referred to as the "Acquisition").
